Novartis‘ (NYSE:NVS) chief executive Joseph Jimenez is slated to leave his post next February, the drugmaker reported over the weekend. The CEO’s surprise departure leaves the corner office to Dr. Vasant Narasimhan, who currently serves as the company’s CMO and global head of drug development.

The move comes just days after Novartis won FDA approval for its breakthrough CAR-T leukemia therapy – the first of its kind to be cleared in the U.S.

Get the full story at our sister site, Drug Delivery Business News.